138326-68-8

Usage

Uses

Used in Pharmaceutical Research and Development:
S-Cyclopropylglycine Methyl ester hydrochloride is used as a building block for the synthesis of biologically active compounds, contributing to the development of new drugs with enhanced pharmacological properties.
Used in Drug Synthesis:
S-Cyclopropylglycine Methyl ester hydrochloride serves as a precursor in the creation of novel pharmaceuticals, leveraging its unique structural features to improve drug efficacy and target specificity.
Used in the Central Nervous System:
S-Cyclopropylglycine Methyl ester hydrochloride is used as a modulator of neurotransmission and synaptic function, potentially offering therapeutic benefits in the treatment of neurological disorders.
Used in the Pharmaceutical Industry:
The hydrochloride salt form of S-Cyclopropylglycine Methyl ester is utilized for its improved solubility and stability, making it a valuable tool in formulating pharmaceutical products with enhanced performance and shelf life.

Upstream product

• 77-76-9 2,2-dimethoxy-propane 
• 155976-13-9 (2S)-2-[[(tert-butoxy)carbonyl]amino]-2-cyclopropylacetic acid 
• 49606-99-7 (S)-2-amino-2-cyclopropylacetic acid 
• 75-36-5 acetyl chloride 
• 67-56-1 methanol 

Downstream Products

• 1093191-55-9 (S)-cyclopropyl-(4-(4-morpholin-4-ylmethylphenylethynyl)benzoylamino)acetic acid methyl ester 
• 1047665-90-6 C₂₆H₃₃FN₂O₅ 
• 1093191-57-1 N-((S)-cyclopropyl(hydroxycarbamoyl)methyl)-4-(4-morpholin-4-ylmethylphenylethynyl)benzamide trifluoroacetate 
• 842131-33-3 ulimorelin 
• 874336-43-3 C₃₀H₃₉FN₄O₄*ClH 
• 874336-35-3 C₃₁H₄₂N₂O₇ 
• 874336-42-2 (R)-2-((R)-2-((S)-2-(((R)-2-(2-(3-aminopropyl)phenoxy)propyl)-amino)-2-cyclopropyl-N-methylacetamido)propanamido)-3-(4-fluorophenyl)propanoic acid 
• 1351469-17-4 C₄₂H₅₅FN₄O₇ 
• 874336-40-0 C₅₀H₆₁FN₄O₉ 
• 874336-36-4 (S)-2-(((R)-2-(2-(3-(((benzyloxy)carbonyl)amino)propyl)phenoxy)-propyl)(tert-butoxycarbonyl)amino)-2-cyclopropylacetic acid 
• 874336-34-2 C₂₆H₃₄N₂O₅ 

Relevant academic research and scientific papers

Macrocyclic Modulators of the Ghrelin Receptor

The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

Palladium(II)-Catalyzed highly enantioselective C-H arylation of cyclopropylmethylamines

C-H arylation via a Pd(II)/Pd(IV) catalytic cycle has been one of the most extensively studied C-H activation reactions since the 1990s. Despite the rapid development of this reaction in the past two decades, an enantioselective version has not been reported to date. Herein, we report a Pd(II)-catalyzed highly enantioselective (up to 99.5% ee) arylation of cyclopropyl C-H bonds with aryl iodides using mono-N-protected amino acid (MPAA) ligands, providing a new route for the preparation of chiral cis-aryl-cyclopropylmethylamines. The enantiocontrol is also shown to override the diastereoselectivity of chiral substrates.

Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from Hit to Clinic

High-throughput screening of Tranzyme Phar-ma's proprietary macrocycle library using the aequorin Ca2+-bioluminescence assay against the human ghrelin receptor (GRLN) led to the discovery of novel agonists against this G-protein coupled receptor. Early hits such as 1 (Ki = 86 nM, EC50 = 134 nM) though potent in vitro displayed poor pharmacokinetic properties that required optimization. While such macrocycles are not fully rule-of-five compliant, principally due to their molecular weight and clogP, optimization of their pharmacokinetic properties proved feasible largely through conformational rigidification. Extensive SAR led to the identification of 2 (Ki = 16 nM, EC50 = 29 nM), also known as ulimorelin or TZP-101, which has progressed to phase III human clinical trials for the treatment of postoperative ileus. X-ray structure and detailed NMR studies indicated a rigid peptidomimetic portion in 2 that is best defined as a nonideal type-I′ β-turn. Compound 2 is 24% orally bioavailable in both rats and monkeys. Despite its potency, in vitro and in gastric emptying studies, 2 did not induce growth hormone (GH) release in rats, thus demarcating the GH versus GI pharmacology of GRLN. (Figure presented)

ANTIBACTERIAL AGENTS

Antibacterial compounds of formula (I) are provided, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.

NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS

Compounds of formula as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R6 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.

Indole nitriles

Compounds of the formula (I) wherein m, n, R1, R2, R3, R4, R5 and R6 are as described herein, together with methods for making the compounds and using the compounds for treatment of diseases or conditions mediated by Cathepsin K.

Benzamide nitriles

Compounds of the formula (I) wherein m, n, A, R1, R2, R3, R4, R5 and R6 are as described herein, together with methods for making the compounds and using the compounds for treatment of diseases or conditions mediated by Cathepsin K.